The indirect comparative analysis is the first of its kind to assess the relative efficacy of approved covalent Bruton tyrosine kinase inhibitors (cBTKis) in the absence of head-to-head trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback